UnitedHealth Group Q2 2026 Earnings: Medicare Improvement Lifts Outlook, but Commercial Cost Pressure Persists

UnitedHealth Group’s second-quarter results showed a meaningful recovery in profitability, driven by stronger-than-expected Medicare Advantage performance, improved Optum Health execution, and actions taken over the past year to reshape benefits and operating costs. Adjusted EPS rose to $6.38 from $4.08 a year earlier, while operating earnings increased 55% to $8B despite total revenue remaining broadly flat at $112B.

The company raised its full-year adjusted EPS outlook to $19.50 to $20.00 and increased operating-income expectations for both UnitedHealthcare and Optum Health. The central offset is commercial insurance, where medical cost trend is now running modestly above 11% and management no longer expects a full return to historic commercial margins by 2027.

As Reported on the Call

The Bigger Story

The quarter suggests UnitedHealth’s turnaround efforts are producing better near-term earnings than management had initially planned for 2026. The most important contributor was Medicare Advantage, where medical costs remain elevated by historical standards but have tracked below the company’s planning assumptions. Better member retention, benefit design, network actions, care management, a favorable respiratory season, and less adverse weather all helped.

Management now expects Medicare Advantage enrollment to decline by approximately 1.1 million for the full year, but forecasts Medicare margins above 3%. That combination is significant: UnitedHealth is accepting lower enrollment as it adjusts benefits and market participation to improve profitability and stabilize the business.

However, the recovery is uneven. Commercial medical costs have not moderated, and management said the commercial margin-recovery timeline has moved beyond 2027. The company still views a return to commercial margins of 7% or more as achievable over time, but that outcome now depends on pricing, administrative efficiencies, affordability efforts, and potential improvement in costly out-of-network billing dynamics.

Revenue and Operating Performance

Total revenue was approximately $112B, largely unchanged from the prior year. The earnings improvement therefore came primarily from margin recovery and operating actions rather than reported top-line expansion.

At UnitedHealthcare, Medicare Advantage was the strongest area during the quarter. Management said retention was better than expected, while medical trend came in below the company’s initial forecast of roughly 10% for 2026. Management attributed the relative improvement partly to its own initiatives, including benefit design, network curation, care management, and changes in membership mix.

The company was careful not to characterize the Medicare result as a broader normalization of medical costs. Management said underlying trend remains high relative to historical levels, and it has not yet provided a revised point estimate for 2026 Medicare trend. Some of the favorable performance also reflected a lighter respiratory season, weather patterns, positive claims experience, and the absence so far of certain risk factors incorporated into planning assumptions.

Medicaid performed broadly in line with expectations. Annualized 2026 rate increases are expected to be in the range of 6% to 7%, according to management, but those increases still trail elevated medical costs. The company expects Medicaid margins to remain negative, within its previously communicated range of negative 1% to negative 1.7%, as pressure continues in specialty pharmacy, behavioral health, home and community-based care, and inpatient skilled nursing services.

Commercial insurance remains the most consequential operating weakness. Medical cost trend is running modestly above 11%, with no meaningful offset from lower utilization elsewhere in the portfolio. Management cited increased provider coding intensity, higher cost per encounter, specialty pharmacy spending, GLP-1 drugs, anti-inflammatory drugs, and the federal independent dispute resolution process under the No Surprises Act.

Management estimated that the dispute-resolution process is contributing roughly 50 basis points of incremental commercial trend in 2026 and at least 100 basis points of total cost. It said the process has become more burdensome as dispute volumes have increased, with 40% of claims entering arbitration deemed ineligible and roughly 60% of cases brought by five entities. Management also said arbiters’ average payouts when siding with out-of-network providers are now 11 times Medicare reimbursement, with some cases reaching 30 times Medicare rates.

Profitability and Margins

Operating earnings increased 55% to $8B, and adjusted EPS rose 56% year over year. The reported medical care ratio improved to 86.7% from 89.4% in the prior-year quarter.

That improvement included $860M of net favorable prior-period medical development, most of which management described as in-year development. This item helped the reported medical care ratio and earnings, although management maintained that its updated $19.50 to $20.00 adjusted EPS outlook represents a durable base rather than a result that should be adjusted for one-time factors.

The operating cost ratio increased to 12.7% from 12.3%. Management said it is continuing to invest in technology, AI, care delivery, customer experience, employees, communities, and the United Health Foundation. The company does not view those investments as temporary, even though it described them as building the foundation for future performance.

Optum Health also contributed to the stronger result. Management said value-based care margins in the first half were in line with, but slightly ahead of, expectations. The improvement reflected care-management initiatives, operating discipline, productivity improvements, and better access to patient care.

One cited initiative reduced hospitalizations by approximately 10% in Optum Health’s Western and Southern regions since its late-2025 implementation. Home-health pilots improved timely care delivery by more than 20%, while reducing acute-care use and shortening skilled nursing facility stays, according to management.

Still, Optum Health’s earnings remain highly seasonal. Management expects nearly all of its 2026 profit in the first half, followed by modest profit in the third quarter and modest losses in the fourth quarter. Restructuring activities and continued investments are also shifting some costs into the second half.

Demand, Customers and Pricing

Optum Rx reported high-90% client retention and said its move toward transparent, fee-based pharmacy benefit management services is resonating with customers. The company expects more than 95% of clients to be on 100% manufacturer-rebate pass-through arrangements by the end of 2026, ahead of its stated goal to pass through all manufacturer rebates by the end of 2027.

At Optum Health, management said contracting discussions with payer partners for the 2027 planning cycle are progressing well. The company has focused on earlier coordination with payers around rates, benefit design, risk arrangements, and geographic footprint. Management said most addressable contracting activity for 2027 is substantially complete, though the economic effect will depend on execution as those arrangements take effect.

Optum Insight was slightly ahead of management’s expectations in the quarter, helped by operational execution, AI-related efficiency gains, and transaction volume that shifted from the second half into the first half. Management did not raise the full-year outlook for the segment, partly because it continues to invest in new AI products and services.

The company highlighted early adoption of AI-enabled products, but these initiatives remain more strategic than material to current earnings. Management said its digital prior-authorization product, launched about a quarter earlier, is already processing authorizations for external customers and saving administrative hours.

What is UnitedHealth’s guidance and outlook?

UnitedHealth raised its 2026 adjusted EPS guidance to $19.50 to $20.00. Management expects somewhat more earnings in the third quarter than in the fourth quarter.

The company also increased its operating-earnings outlook for UnitedHealthcare to at least $12B and for Optum Health to at least $2.2B. It now expects a full-year medical care ratio of 88.1%, plus or minus 25 basis points.

Management expects UnitedHealthcare earnings to remain heavily weighted to the first half of the year, with about 75% of segment earnings recognized in the first six months. Optum Rx and Optum Insight are expected to be more back-half weighted, each generating roughly 55% of annual earnings in the second half as client implementations and seasonality progress.

For Medicare Advantage, management expects 2026 medical trend to finish below its initial estimate of around 10%, but said it will wait for more claims development before providing a new specific estimate. The company said 2027 benefit planning assumes continued elevated underlying medical trend rather than a meaningful decline.

Management reiterated its longer-term goal of 13% to 16% earnings growth, describing the new 2026 EPS range as the appropriate starting point for that framework. That remains a management target, not formal 2027 guidance.

Balance Sheet, Cash Flow and Capital

Operating cash flow was approximately $11B in the quarter, equal to 1.9 times net income. Management said the result benefited from the timing of substantial government payments as well as strong earnings.

UnitedHealth repurchased 11.4 million shares for $4B through mid-July and now expects at least $5B of share repurchases in 2026, up from initial guidance of $2.5B. The company also returned $2.1B through dividends in the quarter and raised the annualized dividend to $9.28 per share.

The debt-to-capital ratio declined to 41.2% from 44.1% a year earlier. Management remains on track to reduce the ratio to approximately 40% by year-end. The company also completed its previously announced acquisition of Alegeus on July 2.

What Investors Should Watch

1. Commercial Medical Cost Trend

Commercial trend above 11% is the clearest obstacle to broader margin recovery. Investors should watch whether pricing, utilization management, coding controls, and administrative efficiencies begin to offset pressure from provider billing practices, specialty pharmacy, and the No Surprises Act dispute process.

2. Medicare Margin Durability

Medicare Advantage performance exceeded management’s planning assumptions, but favorable seasonal and claims factors contributed. The key question is whether benefit design, network curation, and care management can sustain margins above 3% as medical costs remain elevated and enrollment declines.

3. Optum Health’s Second-Half Seasonality

Optum Health’s first-half performance improved, but management expects modest third-quarter profit and a modest fourth-quarter loss. Execution on restructuring, clinical initiatives, and operational investments will determine whether the segment can convert its early improvement into a more durable margin recovery.

4. Medicaid Rate Adequacy

Rate increases of 6% to 7% are still expected to lag medical-cost inflation. Progress in state reimbursement negotiations and cost-management efforts will be necessary for Medicaid margins to move out of their projected negative range.

5. AI Investment Returns

UnitedHealth is investing heavily in AI across claims, prior authorization, care management, clinical documentation, and Optum Insight products. Investors should look for measurable evidence that these programs lower administrative costs, improve service levels, reduce clinician burden, or create external software and services revenue rather than remaining primarily an investment narrative.

AlgovestIQ Takeaway

UnitedHealth’s second quarter showed a stronger operating recovery than its flat revenue figure suggests. Medicare Advantage performance improved, Optum Health is showing early evidence of better clinical and operating execution, and the company raised its 2026 earnings outlook while accelerating share repurchases.

The quality of that improvement deserves some caution. The medical care ratio benefited from $860M of favorable prior-period development, and Medicare results also reflected seasonal and claims-related factors that may not recur. Management argues that the $19.50 to $20.00 EPS range is a durable baseline, but investors will need to see the second half confirm that view.

Commercial insurance is now the main unresolved issue. Management’s admission that full commercial margin recovery will take longer than previously expected, extending beyond 2027, changes the near-term earnings mix and raises the importance of execution in Medicare and Optum. Persistent commercial cost inflation could limit the company’s ability to translate operational initiatives into broad-based margin expansion.

The investment case has therefore shifted from a simple recovery narrative to a more selective execution story. Evidence that Medicare margins remain durable, Optum Health can manage its second-half seasonality, and commercial cost trends begin to stabilize would strengthen confidence in management’s long-term growth framework. Continued commercial pressure, inadequate Medicaid reimbursement, or an earnings decline in Optum Health beyond the expected seasonal pattern would weaken it.